The value of circulating levels of SDC1 was not consistently associated with tumor grade or characteristics, but the combination of SDC1 and bFGF/FGF2 in patient serum has a strong association with tumor progression and prognosis in selected cancer types. This evidence concerns the gene FGF2 and neoplasm.